-
EU-US mutual recognition agreement extended
EU-US mutual recognition agreement extended
-
EU-US mutual recognition agreement extended
EU-US mutual recognition agreement extended
The agreement allows EU and US authorities to recognise each other’s inspections of manufacturing facilities of some veterinary medicines
-
Adapting COVID-19 vaccines to future variants
Adapting COVID-19 vaccines to future variants
-
Adapting COVID-19 vaccines to future variants
Adapting COVID-19 vaccines to future variants
Global regulators agreed on a way forward to adapt COVID-19 vaccines to future variants, during a workshop co-chaired by EMA and the FDA, under the umbrella of ICMRA
-
CHMP highlights: May 2023
CHMP highlights: May 2023
-
CHMP highlights: May 2023
CHMP highlights: May 2023
EMA's human medicines committee (CHMP) recommended 2 new medicines for approval in the EU at its May 2023 meeting
-
2022 annual report published
2022 annual report published
-
2022 annual report published
2022 annual report published
EMA has published its 2022 annual report that provides an overview of the Agency’s major achievements, key figures and contributions to public and animal health in Europe
Information for you
Key content
Services & databases
-
List item
Clinical Trials website
-
List item
Account Management portal
-
List item
eSubmission
-
List item
EudraVigilance (human)
-
List item
EudraVigilance Veterinary
-
List item
Veterinary Medicines information website
-
List item
Suspected adverse drug reactions database
-
List item
Clinical data
-
List item
SPOR data management services
-
List item
Service Desk
-
List item
IRIS platform
-
List item
Public register of parallel distribution notices
-
List item
European Vaccination Information Portal